1. Home
  2. GLOB vs IRON Comparison

GLOB vs IRON Comparison

Compare GLOB & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globant S.A.

GLOB

Globant S.A.

HOLD

Current Price

$46.55

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$64.74

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLOB
IRON
Founded
2003
2017
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.3B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
GLOB
IRON
Price
$46.55
$64.74
Analyst Decision
Buy
Strong Buy
Analyst Count
14
11
Target Price
$78.64
$103.18
AVG Volume (30 Days)
1.1M
445.3K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.06
N/A
Revenue Next Year
$5.30
$283.52
P/E Ratio
$22.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$40.77
$30.82
52 Week High
$142.25
$99.50

Technical Indicators

Market Signals
Indicator
GLOB
IRON
Relative Strength Index (RSI) 46.84 53.83
Support Level $41.39 $57.79
Resistance Level $71.47 $69.36
Average True Range (ATR) 2.16 2.76
MACD 0.61 0.92
Stochastic Oscillator 82.44 73.17

Price Performance

Historical Comparison
GLOB
IRON

About GLOB Globant S.A.

Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: